Objective: To investigate the mechanism of aggrecanolysis in interleukin-1 (IL-1)-treated cartilage tissue by examining the time course of aggrecan cleavages and the tissue and medium content of membrane type 4-matrix metalloproteinases (MT4-MMP) and a disintegrin and metalloproteinase with thrombospondin type I motifs (ADAMTS)4.
Introduction
Enhanced release of proteoglycans from the articular cartilage to the synovial fluid is a prominent feature of early and late osteoarthritis. In particular, aggrecan is the most abundant proteoglycan in cartilage tissue and provides much of the tissue's compressive strength through electrostatic repulsion of its tightly packed glycosaminoglycan (GAG) chains 1 . Excess degradation of aggrecan in the cartilage tissue thus contributes directly to the failure of the mechanical function of the joint.
Investigation of enzymatic degradation of aggrecan has led to the identification of specific cleavage sites generated by enzymes termed aggrecanases, which have since been identified as a sub-group (ADAMTS1, 4, 5, 8, 9, 15) [2] [3] [4] of the 19member family of ADAMTS (a disintegrin and metalloproteinase with thrombospondin type I motifs) proteinases 5, 6 . It is now clear that degradation of aggrecan induced by major inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor is mediated by the action of the aggrecanases and not the matrix metalloproteinases (MMPs) 7e10 . In addition, the evidence for aggrecanasemediated cleavage of aggrecan in cartilage tissue and synovial fluid from patients with osteoarthritis 11, 12 suggests that aggrecanase activity is predominantly or maybe exclusively responsible for the excess degradation of cartilage aggrecan which is a feature of human osteoarthritis.
Recently, the steps involved in processing of ADAMTS4 (aggrecanase-1) have been described in a human chondrosarcoma cell line stably transfected with ADAMTS4, and the aggrecanase activities of the processed forms characterized. To exhibit any aggrecanase activity, the ADAMTS4 proenzyme first requires intracellular furin-mediated removal of the N-terminal pro-domain 13 , which generates the p68 form. While this form can degrade the C-terminal chondroitin sulfate (CS)-bearing region, it appears that for ''destructive'' cleavage of aggrecan in the interglobular domain (IGD), further C-terminal truncation of ADAMTS4 is required 2, 14, 15 , producing the p53 and p40 forms of the proteinase. We have previously hypothesized that this Cterminal truncation requires a glycosylphosphatidylinositol (GPI)-linked MMP, since IGD cleavage is blocked by inhibitors of GPI anchor synthesis such as mannosamine (ManN) and by MMP inhibitors 2, 16 . This was recently supported by the finding that transfection of ADAMTS4expressing cells with membrane type 4-MMP (MT4-MMP) (a GPI-anchored MMP 17 ) promoted C-terminal processing of ADAMTS4 to the p53 and p40 forms and acquisition of IGD cleavage activity 18 .
However, there has been no detailed description of the processing of ADAMTS4 in native cartilage tissue. Initial studies of the protein forms present in normal and IL-1stimulated cartilage have shown evidence for ADAMTS4 forms in the ranges 30e60 kDa 9 and 37e46 kDa 14 , and the effect of IL-1 treatment on levels of MT4-MMP protein in cartilage has not been reported.
We therefore examined aggrecan degradation in newborn bovine cartilage explants treated with IL-1 by Western analysis of aggrecan, ADAMTS4 and MT4-MMP in the cartilage tissue and conditioned medium. In addition, we examined the effects of two aggrecanase blockers, ManN 16, 19, 20 and esculetin (EST) 21 . We hypothesized that as an inhibitor of GPI anchor synthesis 16, 20, 22 , ManN would interfere with the processing of the p68 form to the p53 form. The mechanism for aggrecanase inhibition by EST is not clear but it appears to inhibit MMP gene expression 21, 23 , and thus allows investigation of the effects of aggrecanase blockade through what is likely a different mechanism than ManN. Finally, to investigate regulation of aggrecanase activity at the level of transcription, we measured the effect of IL-1 and ManN treatment on mRNA expression of ADAMTS4 and ADAMTS5 by realtime PCR analysis.
Methods

MATERIALS
Human recombinant IL-1a was from R&D Systems, Inc., Minneapolis, MN. Unless indicated, other reagents were from Sigma Chemical Co. (St. Louis, MO).
CARTILAGE EXPLANT AND CULTURE
Articular cartilage disks were obtained from the femoropatellar groove of one-to-two-week-old calves, a model system that has been widely studied to examine the biological response pathways relevant to cartilage degradation in human osteoarthritis 24 , using methods similar to those described in detail previously 25 . In brief, 9-mmdiameter cylinders of full-thickness cartilage and bone were cored from the articular cartilage. After slicing off sufficient superficial cartilage to create a flat surface (usually less than 500 mm), the next two sequential 0.5-mm-thick slices were cut with a sledge microtome. From each of these slices, four cartilage disks (3 mm in diameter and 0.5 mm in thickness) were cut out with a dermal punch. Groups of cartilage disks were incubated at 37(C in an atmosphere of 5% CO 2 , in wells containing 0.25 ml/disk of a serum-free culture medium (low-glucose DMEM [Dulbecco's modified Eagle's medium] [Gibco, Grand Island, NY] and 10 mM HEPES buffer, with 100 U/ml penicillin G, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin B). Experimental treatments with IL-1 and aggrecanase blockers were begun on the day of harvest. With the exception of the kinetic analysis, these cultures were incubated without medium replacement for up to 6 days. Each experiment had four to eight treatment groups, allowing disks among different groups to be matched for their original location along the surface of the joint.
BIOCHEMICAL ANALYSIS OF PROTEOGLYCANS
Tissue and medium were analyzed for composition of aggrecan fragments by Western blotting as previously described 26 . Aggrecan remaining in the cartilage tissue was extracted in 4 M guanidine (1.2 ml per 75 mg wet weight) for 48 h at 4(C in the presence of proteinase inhibitors. Aggrecan fragments in tissue extracts and conditioned medium were isolated by ethanol precipitation and deglycosylated. Portions of medium and tissue extracts (corresponding to 10 mg GAG in each case) were loaded on 4e12% polyacrylamide gels (Novex) for Western analysis and probed with polyclonal antisera to the bovine G1 domain (G1-2), the G3 domain (antibody LEC-7, provided by Dr Kurt Doege) and the C-terminal neoepitopes TFKEEE 1706 (antiserum provided by Merck), TAGELE 1520 (antiserum provided by DuPont), and NITEGE 392 (antibody JSCNIT). Tissue (digested overnight with proteinase K) and conditioned medium were assayed for sulfated GAG content by reaction with dimethylmethylene blue (DMMB) dye.
WESTERN ANALYSIS OF ADAMTS4 (AGGRECANASE-1) AND MT4-MMP
Pilot studies were done to optimize the extraction conditions for ADAMTS4 in cartilage. Cartilage (15 mg wet weight) was freeze-milled in a Biopulverizer (Biospec Products, Bartlesville, OK) and the powder was extracted for 20 h at 4(C in three volumes (ml/mg wet weight) of (1) 50 mM TriseHCl, pH 7.0; (2) 50 mM TriseHCl, 100 mM NaCl, pH 7.0; (3) 50 mM TriseHCl, 100 mM NaCl, 0.5% Nonidet P-40, pH 7.0; or (4) 4 M guanidine, 50 mM TriseHCl, pH 7.0. Macromolecules in the 4 M guanidine extract were purified by Sephadex G50 and DE 52 as previously described for aggrecan fragments 27 and the unbound (protein) and bound (proteoglycan) fractions were analyzed. Other cartilage samples were treated at 100(C for 10 min in 50 mM TriseHCl and 2.5% SDS. The results of the comparative extraction experiments (not shown) indicated that the highest yield of immunoreactive product was consistently obtained with extractant (3). Poor recoveries were seen with 4 M guanidine extracts and boiling in SDS. Therefore, all data shown in the present paper were obtained using extraction with 0.5% Nonidet P-40, 50 mM Tris, and 100 mM NaCl at pH 7.0, and dilution of 5e10 ml of the extracts in gel-loading buffer before SDS-PAGE (sodium dodecyl sulfateepolyacrylamide gel electrophoresis). Conditioned medium from cartilage explants was concentrated by lyophilization, dialyzed, dried and dissolved in gel-loading buffer.
Western analysis of ADAMTS4 was done with two affinity-purified antibodies that exhibit different reactivities for the molecular forms of ADAMTS4 2 . JSCVMA was raised to a peptide (Val 394 ePro 403 ) in the catalytic domain, and it preferentially reacts with the p53 form in tissue extracts. JSCYNH was raised to a peptide (Tyr 590 ePro 603 ) within the Cys-rich region and it reacts preferentially with the p68 form. All soluble samples were loaded on an equivalent tissue weight basis and separate blots were probed with JSCYNH or JSCVMA. For Western analysis of MT4-MMP (MMP-17), blots were probed with antibodies to MT4-MMP from Sigma (catalog #M3684).
REALTIME PCR ANALYSIS
RNA was extracted from cartilage disks after 24 h of treatment and analyzed by realtime PCR. Frozen cartilage was pulverized and then homogenized in Trizol reagent (Invitrogen, Carlsbad, CA). After addition of 10% v/v chloroform, the samples were centrifuged at 13,000 g for 10 min in phase-lock gel tubes (Eppendorf AG, Hamburg, Germany). The aqueous supernatant was collected, and RNA was isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA). Extracted RNA concentration and purity was measured by optical density at 260 and 280 nm. Equal quantities of RNA from each sample were reverse transcribed with the Amplitaq Gold RT kit (Applied Biosystems, Foster City, CA). Realtime PCR was performed with the Applied Biosystems 7700 instrument and SYBR Green Master Mix (Applied Biosystems). Primers were designed as described previously 28 .
For statistical analysis of mRNA expression levels, mRNA copy number was first log-transformed to normalize the distribution of the data. Since the experiment was designed as a factorial experiment, linear regression was performed to test for the effects of the two factors (ManN and IL-1) as well as for an interaction between the effects of ManN and IL-1. Two indicator variables were also included to adjust for proportional changes in baseline between experiments.
Results
KINETICS OF AGGRECAN DEGRADATION IN CALF EXPLANTS TREATED WITH IL-1
In preliminary experiments to describe the kinetics of IL-1-induced aggrecan degradation in the newborn bovine cartilage tissue, we obtained cartilage disks with a defined cylindrical geometry and treated them with 1, 10 and 100 ng/ml IL-1a. At 2, 4, and 6 days the cultures were terminated and the proportion of total GAG remaining in the tissue as well as the equilibrium and dynamic compressive moduli were measured. This analysis (data not shown) revealed that for explants cut to 0.5 mm in thickness, the addition of IL-1 at 10 ng/ml generated a gradual catabolic response which was most appropriate for kinetic analysis over 6 days.
We therefore treated cartilage explants with 10 ng/ml for 6 days and terminated cultures at eight different times (0, 0.5, 1, 1.5, 2, 2.5, 3, 4.5, and 6 days), with removal of medium and replacement with fresh medium and IL-1 at days 2 and 4.5. To examine the composition of aggrecan remaining in the tissue at these times, we performed a Western analysis with anti-aggrecan G1 domain on the tissue extracts [ Fig. 1(A) ]. The composition of the control tissue (maintained in culture without IL-1 for 6 days) and fresh tissue (maintained for 0 days) was primarily core species 1 (full-length aggrecan) with a low abundance of species a, b, c and d, which are not generated by aggrecanase action (see Fig. 2 for peptide notations). Early in the IL-1 treatment period (days 1 and 1.5), species a and b appeared to be eliminated from the tissue, whereas from days 2e6 there was an accumulation in the tissue of species 5 (G1-TAGELE) at about 250 kDa. Western analysis of these samples with anti-TAGELE and anti-TFKEEE confirmed that the abundance of these aggrecanase-generated species (at about 200e250 kDa) was increased during days 2e6, in parallel with the appearance of the G1-reactive band(s) in that region of the gel (data not shown). Interestingly, the N-terminal product G1-NITEGE (species 6 doublet) was not observed until day 4.5 of culture, consistent with the common finding that IL-1promoted aggrecanase-mediated aggrecan degradation occurs in a stepwise fashion, with the C-terminal region being degraded before cleavage of the IGD 9, 16, 29 .
This interpretation was supported by Western analysis of the medium collected over various periods during this culture with an antibody to the G3 domain [ Fig. 1(B) ]. The ''ladder'' of G3-reactive species labeled as 7, 8, 9, and 10 are characteristic of aggrecanase-mediated C-terminal processing during the early period (days 0e3), whereas the relative paucity of these products in medium collected after day 4.5 is consistent with aggrecanase cleavage now being targeted to the IGD. This was verified by Western analysis of the medium for the G1 domain, which showed nearly undetectable G1-NITEGE release until day 4.5, and no evidence for higher-molecular-weight G1-bearing fragments (data not shown), as observed in this system previously 30 . An unidentified G3-reactive fragment at about 44 kDa was a major medium product at all time periods, and this migration behavior is consistent with the isolated globular region of the G3 domain of bovine aggrecan. The proteinase responsible for the generation of this species is unknown; however, the same or similar product is readily generated from bovine aggrecan by m-calpain digestion 31 . Analysis of the tissue extracts with the anti-G3 antibody detected only the full-length core protein (data not shown), suggesting that these G3-bearing fragments diffuse rapidly into the medium once formed.
ANALYSIS OF EXPLANT SYSTEM FOR ADAMTS4 PROTEIN
Since it was clear that an active aggrecanase was present in this system, and since it has been suggested that ADAMTS4 (rather than TS-1, 5, 8, 9 or 15) is mostly responsible for this activity 4, 9, [32] [33] [34] [35] , we analyzed both tissue and medium for ADAMTS4 in control cultures, IL-1-treated cultures, and IL-1-treated cultures with the addition of 1.35 mM ManN. Consistent with our previous findings 29 , in this experiment GAG released from the cartilage to the medium increased from 24 G 2 mg/disk in controls to 115 G 6 mg/disk in IL-1-treated cultures, and this aggrecanase-mediated degradation was blocked by the addition of ManN (40 G 3 mg/disk; all N Z 4 disks per group).
Extracts of untreated control tissue at days 0 and 6, probed with JSCYNH ( Fig. 3, tissue) , contained a single major immunoreactive protein which was identified as the p68 form. Since this antibody reacts with the proenzyme in cell culture experiments, the absence of immunoreactive proenzyme here suggests that either the proenzyme does not accumulate in the tissue or it is poorly reactive in these extracts, perhaps due to the presence of masking proteins. After 6 days of IL-1 treatment, the p68 form was essentially eliminated from the tissue, a process which was markedly blocked by the inclusion of ManN. Analysis of the medium showed that under control conditions, some of the p53 form (and an unidentified fragment of about 30 kDa) was released from the tissue, unlike the p68 form, which remained associated with the tissue. In marked contrast, abundant p68 and p53 were released into the medium after treatment with IL-1 for 6 days; however, the inclusion of ManN returned this process to control levels.
ANALYSIS OF EXPLANT SYSTEM FOR MT4-MMP PROTEIN
To examine the possibility that GPI-anchored MT4-MMP is involved in processing of ADAMTS4 in bovine cartilage, the tissue and conditioned medium from this experiment were further examined by Western analysis for MT4-MMP (MMP-17) protein (Fig. 4) . In fresh tissue (day 0), a trace amount of MT4-MMP protein was detected, whereas in control tissue and medium at 6 days it was not detectable. In contrast, analysis of tissue treated with IL-1 showed a marked increase in MT4-MMP abundance at w65 kDa (a size consistent with previous observations in cells and 
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1499 LGQRPP 1 Fig. 2 . Schematic of the structures for bovine aggrecan core protein peptides. The diagram shows the currently accepted structures for aggrecan core protein peptides derived from bovine cartilage explants before and after treatment with IL-1 (see Fig. 1 ). The sequences and residue numbers shown are taken from data in Hering et al. 50 for bovine aggrecan (accession number AAB38524), and the identifications are taken from Oshita et al. 31 and references therein. Note that these residue numbers differ from previous reports 11 Fig. 3 . Western analysis of ADAMTS4 in cartilage tissue and conditioned medium with JSCYNH. Cartilage was analyzed immediately after harvest (Day 0) or incubated for 6 days in serum-free medium with no treatment, 10 ng/ml IL-1, or IL-1 plus 1.35 mM ManN. Conditioned medium was concentrated and loaded on an equal volume basis (500 ml). IL-1 treatment resulted in a loss of tissue p68 to the medium and an increase in abundance of the p53 in the medium that was blocked by addition of ManN.
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P. Patwari et al.: Involvement of MT4-MMP in activation of ADAMTS4 tissues 18, 36 ). This increase in protein abundance was largely reversed on addition of ManN. Similarly, analysis of the collected conditioned medium showed an increased abundance of MT4-MMP protein in IL-1-treated cultures that was blocked by inclusion of ManN. The nature of the minor immunoreactive product at w80 kDa is unknown.
EFFECT OF EST ON IL-1-INDUCED CHANGES
EST (dihydroxycoumarin) has previously been shown to inhibit cartilage degradation induced by the combination of IL-1 and oncostatin M, but the mechanism is not clear 21, 23, 37 . We therefore performed a parallel set of experiments, first demonstrating inhibition of IL-1-induced aggrecanase activity by EST, and then testing whether EST also reversed IL-1-induced changes in ADAMTS4 and MT4-MMP protein. Cartilage explants were incubated in the presence or absence of 10 ng/ml IL-1 and EST for 6 days, with doses from 31 mM to 500 mM EST. EST was solubilized in dimethylsulfoxide (DMSO) at a concentration sufficient to ensure that the final concentration of DMSO did not exceed 0.5% in any culture medium.
EST inhibited GAG loss from tissue in a dose-dependent manner [ Fig. 5(A) ], and had marked effects on both the abundance and distribution of ADAMTS4 [ Fig. 5(B) ] and MT4-MMP [ Fig. 5(C) ]. In this experiment, the control cartilage contained the p68 form of ADAMTS4, and no detectable ADAMTS4 was released during culture for 6 days. In the presence of IL-1, there was a loss of p68 from the tissue and appearance of p53 in the medium. While the Western analysis suggests an increase in total immunoreactive ADAMTS4, this may be misleading since the antibody used (JSCVMA) reacts preferentially with the p53 form (see Methods). EST markedly blocked this IL-1-mediated conversion and release process at 31 mM and completely blocked it at 125 mM. In keeping with these profound effects of EST on ADAMTS4, the abundance of MT4-MMP in the tissue (very little was found in the medium) was markedly (more than 10-fold) enhanced by IL-1 treatment and this effect was blocked by EST in a dose-dependent manner over the concentration range tested.
REALTIME PCR ANALYSIS
To examine the possibility that the ManN blockade of IL-1 mediated aggrecanase activity in bovine cartilage explants could be due to transcriptional inhibition we carried out realtime PCR of ADAMTS4 and ADAMTS5 in this system. The data (Fig. 6) shows that for both aggrecanases there was a marked (w3-fold for ADAMTS4 and w10-fold for ADAMTS5) increase in transcription 1 day after addition of 10 ng/ml IL-1 (P ! 0.001 for both). There was no significant effect of ManN treatment alone, but ManN significantly inhibited the IL-1-induced increase in ADAMTS4 (P Z 0.047) and showed the same trend for ADAMTS5 (P Z 0.052). 273 Osteoarthritis and Cartilage Vol. 13, No. 4 
Discussion
IMPLICATIONS FOR ADAMTS4 PROCESSING AND THE MECHANISM OF AGGRECANOLYSIS
The data provided both confirm and extend current models for the synthesis, processing and mode of action of ADAMTS4 in aggrecan degradation. The importance of the present work is that it provides evidence that the model established in recombinant cell expression systems 2,14,18 is supportable when examined in live cartilage tissue in explant culture.
The central features of this model include a secreted furin-cleaved p68 protein 2,13 which cannot cleave the IGD of aggrecan but which has high activity toward the CSattachment region 14, 18 . This p68 form can be presented on the cell surface in association with MT4-MMP 18 where it is C-terminally cleaved by MT4-MMP to generate the p53 form, which can be found in association with syndecan-1 18 , and which readily cleaves at the IGD site of aggrecan to destroy the biomechanical properties of the tissue 29 . The MT4-MMP-mediated cleavage sites are the same as those shown to occur during autoproteolysis of ADAMTS4 15, 18 .
In the present work we have shown that in a cartilage explant, the IL-1-promoted and aggrecanase-mediated sequential cleavage of the C-terminal and IGD of aggrecan [ Fig. 1(A, B) ] is not accompanied by a marked change in the amount of ADAMTS4 protein but, in agreement with the studies of Pratta et al. 7 , it appears to be due to activation of an existing pool of enzyme [ Figs. 3 and 5(B) ]. The changes induced by IL-1 were in the p68 form and the p53 form ( Fig. 3) , both of which were found in the medium compartment after 6 days. In time-course experiments (not shown) the p68 form was found to be abundant at day 2 whereas the p53 form was only apparent after 6 days. Given that the p68 form is confined to C-terminal cleavage of aggrecan 14 , the kinetics of appearance of the p68 and p53 seen here are consistent with the finding that C-terminal cleavage occurred early in the process [ Fig. 1(B) ] and this was followed after about 4 days by IGD cleavage [Fig. 1(A) ]. These data, on detergent extracts of cartilage tissue, show some differences from previous observations of increased abundance of guanidine-extractable ADAMTS4 at 46 kDa 14 or at w60 and 30 kDa 9 , which may be explained by variable recovery of ADAMTS4 forms depending on the extractant.
Of particular interest is the finding that both the p68 form and the p53 form are released into the culture medium, suggesting that their proposed cell surface associations with MT4-MMP and syndecan-1, respectively 18 , are saturable and/or reversible. Regarding the association of p68 with MT4-MMP, it is clear that MT4-MMP also increases in abundance in the presence of IL-1 ( Fig. 4) and that a proportion of this newly synthesized GPI-anchored protein is released from the cell and matrix under IL-1 stimulation. While the p68eMT4-MMP complex can be released intact from human chondrosarcoma cells by treatment with phosphatidylinositol-specific phospholipase C 18 , it is unknown whether the two proteins remain associated after MT4-MMP release from the cell surface in the present system. Interestingly, Itoh et al. 17 have observed in COS cells that the release of MT4-MMP from the cell surface is partially inhibited by a metalloproteinase inhibitor, suggesting that a member of the ADAM family of sheddases 38 might also be involved in the aggrecanase cascade. Alternatively, membrane vesiculation during IL-1 treatment 39 might provide an explanation for the release of the MT4-MMP.
While the p68 form is found in both the tissue and the medium, it appears that the p53 form is only abundant in the medium, suggesting that all of the newly formed p53 dissociates from the cell surface syndecan-1 at some time in the process. Again, while the association of p53 with the GAG chains of syndecan-1 in chondrosarcoma cell culture is stable to bi-directional immunoprecipitation protocols 18 , it is not known whether the p53 in the cartilage explant is released into the medium in association with syndecan-1 and/or aggrecan products. Elucidation of the binding partners for the p68 and p53 forms in cartilage explants, along with immunohistochemical characterization of the spatial and temporal aspects of proteinase location and substrate cleavage, will be required to fully understand this complex pathway.
INHIBITION OF THE AGGRECANOLYSIS PATHWAY
The data reported also provide novel insight into the mechanism by which inhibitors of the aggrecanase pathway may operate. The findings that MMP inhibitors (such as TIMP-1, peptide hydroxamates, etc.) can partially block aggrecanolysis in tissue explants suggested early that either MMP inhibitors can directly inhibit the ADAMTS4 catalytic domain, or alternatively that an MMP might be involved in activation of aggrecanase 30,40e42 . In support of this, in the present study we have shown that EST, an inhibitor of MMP-1, 3, and 13 gene transcription 21, 23 is also an inhibitor of aggrecanolysis [ Fig. 5(A) ], p53 ADAMTS4 formation [ Fig. 5(B) ] and MT4-MMP protein accumulation [ Fig. 5(C) ]. Since the IC50 is about 50 mM for each of these three effects, it seems likely that the EST effect operates primarily by blocking induction of MT4-MMP synthesis by IL-1, which results in a lack of conversion of p68 to p53, and a consequent loss of destructive aggrecanolysis. The concentrations of EST required to block cartilage resorption were not due to cytotoxic effects. It has previously been reported that EST concentrations of up to 500 mM had no effect on chondrocyte viability by measurement of LDH (lactate dehydrogenase) release 21 . In addition, we have shown in preliminary experiments that 500 mM EST does not affect expression of TIMP-1 and GAPDH mRNAs as measured by realtime PCR, indicating that transcription had not been universally altered, and suggesting that the inhibition by EST was not based on cytotoxic activity.
The other inhibitor studied here was ManN, which we have suggested 16, 18 exerts its effect by inhibition of the GPI anchor formation required for membrane insertion of MT4-MMP. The present data are consistent with this idea since 1.35 mM ManN markedly (w80%) inhibited the IL-1induced production of MT4-MMP ( Fig. 4) in the cartilage. This predictably blocked the IL-1-induced accumulation of p68 and p53 ADAMTS4 in the medium (Fig. 3) . Interestingly, in the presence of ManN there is a complete blockade of IGD cleavage by p53; however, some C-terminal cleavage to G1-TAGELE is observed (data not shown). This is consistent with the idea that the pre-existing p68 would likely be active in the presence of ManN, since it would not require further GPI anchor formation.
Finally, we show here ( Fig. 6 ) that IL-1 treatment of bovine chondrocytes in cartilage explants results in major upregulation of mRNA for both ADAMTS4 (3-fold) and ADAMTS5 (10-fold). This marked increase in transcriptional activity for these proteinases was not accompanied by major changes in the abundance of these proteins (data not shown for ADAMTS5). This is consistent with the general view that control of aggrecanolysis in cartilage by inflammatory mediators such as IL-1, is initiated by proteinase processing on the cell surface and release of active enzyme into the matrix. Presumably prolonged exposure to such mediators in joint diseases, with an attendant upregulation of transcription, generates a continuous supply of newly synthesized enzyme, which will maintain the activity of this degradative cascade.
The upregulation of ADAMTS5 mRNA observed here is not necessarily indicative of an increase in ADAMTS5 activity, but emphasizes that while the data presented here has focused on activation of ADAMTS4, other family members may also play a role in aggrecanolysis. In particular, the recent findings in mice that the IL-1-induced aggrecanase pathway to G1-NITEGE formation is apparently not blocked by gene deletion of ADAMTS1 43 or ADAMTS4 44 suggest that further analysis of the expression and activation of the individual aggrecanases (ADAMTS1, 4, 5, 8, 9, 15) will be needed to fully define the role of MT4-MMP in the aggrecanolysis associated with human osteoarthritis.
As a general comment, it is important to note that the effectiveness of ManN in this process should not be interpreted as suggesting the use of ManN in place of glucosamine for therapy of human osteoarthritis. ManN, unlike glucosamine, is a potent inhibitor of GPI-anchor synthesis 16 , which is necessary for the anchoring and function of multiple essential cell-surface proteins 45, 46 . ManN ingestion is therefore likely to have profound side effects, which should preclude its use as a therapeutic.
Our evidence for the involvement of MT4-MMP in aggrecanolysis in cartilage tissue culture also has implications for the interpretation of MMP inhibitor studies. For example, some ''broad-spectrum'' MMP inhibitors reportedly do not inhibit aggrecanase activity 40 . However, it is not clear whether all broad-spectrum MMP inhibitors are active against MT-MMPs, which were not characterized until 1999, and may have some unique features in the structure of their catalytic domains 47 . It is therefore intriguing that CGS20723A, a broad-spectrum MMP inhibitor that potently inhibits the catalytic domain of MT4-MMP in solution 48 , does not appear to inhibit overall IL-1-induced GAG loss in tissue culture, but has been reported to protect against loss of pericellular GAG staining 49 . This could be explained if loss of pericellular GAG staining is due to p53 generated by MT4-MMP, whereas more generalized aggrecanolysis in the intercellular matrix is due to p68 and therefore confined to the C-terminal of aggrecan. Thus, the requirement for MT4-MMP for aggrecanolysis suggested by the present data may not extend to all experimental situations, and the development of specific small-molecule MT-MMP inhibitors may in future be useful for testing these hypotheses.
